AnneKerneur

Anne Kerneur's practice focuses on venture capital and capital markets. For more than a decade, she has represented technology, life sciences, and other growth companies, as well as the venture firms and industrial investors that fund them, at every stage of development, from entrepreneurial start-ups to public companies. Anne also regularly advises public companies on governance and executive compensation matters.

Anne's experience includes advising high-growth companies in connection with their financing rounds such as Lithium de France, Arverne Group, Indy.fr, Ankorstore, Shippeo, Akeneo, and TreeFrog Therapeutics and venture capital investors or strategic investors such as TilT Capital, Alven, Creadev, ETF, Hi Inov, Idinvest/Eurazeo, Quadrant Management, Ring Capital, Sofinnova Partners, Seventure, and BNPP.

Illustrative transactions in which Anne acted as lead or co-lead lawyer includes: the €44 million series B financing of Lithium de France led by Equinor and Hydro, the €40 million financing round of EODEV led by TilT Capital, the €250 million financing round of Ankorstore led by Bond and Tiger, and the €35 million financing round of Selency led by Creadev. Anne also advised Arverne Group in its IPO on Euronext in Paris by way of DeSPAC and its €130 million private placement, Cellectis on its US$20 million public offering on Nasdaq, and Integragen in the successful public tender offer of shares by OncoDNA. She also worked on the IPO of Criteo on Nasdaq and the recent IPO of EUROAPI on the main French market.